Department of Otolaryngology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242-1078, USA.
Transl Oncol. 2008 Dec;1(4):202-8. doi: 10.1593/tlo.08163.
The presence of cervical lymph node metastases in head and neck squamous cell carcinoma (HNSCC) is the strongest determinant of patient prognosis. Owing to the impact of nodal metastases on patient survival, a system for sensitive and accurate detection is required. Clinical staging of lymph nodes is far less accurate than pathological staging. Pathological staging also suffers limitations because it fails to detect micrometastasis in a subset of nodal specimens. To improve the sensitivity of existing means of diagnosing metastatic disease, many advocate the use of molecular markers specific for HNSCC cells. MicroRNA (miRNA) are short noncoding segments of RNA that posttranscriptionally regulate gene expression. Approximately one third of all miRNA will exhibit substantial tissue specificity. Using a quantitative reverse transcription-polymerase chain reaction-based assay, we examined the expression of microRNA-205 (mir-205) across tissues and demonstrated that its expression is highly specific for squamous epithelium. We applied this assay to tissue samples, and we could detect metastatic HNSCC in each positive lymph node specimen, whereas benign specimens did not express this marker. When compared to metastases from other primary tumors, HNSCC-positive lymph nodes were distinguishable by the high expression of this marker. Using an in vitro lymphoid tissue model, we were able to detect as little as one squamous cell in a background of 1 million lymphocytes. By combining the sensitivity of quantitative reverse transcription-polymerase chain reaction with the specificity of mir-205 for squamous epithelium, we demonstrate a novel molecular marker for the detection of metastatic HNSCC.
头颈部鳞状细胞癌(HNSCC)中颈部淋巴结转移的存在是患者预后的最强决定因素。由于淋巴结转移对患者生存的影响,需要一种敏感且准确的检测系统。与病理分期相比,临床分期的准确性要差得多。病理分期也存在局限性,因为它无法检测到部分淋巴结标本中的微转移。为了提高现有诊断转移性疾病方法的灵敏度,许多人提倡使用针对 HNSCC 细胞的特异性分子标志物。miRNA(microRNA)是 RNA 的短非编码片段,可在后转录水平调节基因表达。大约三分之一的 miRNA 具有显著的组织特异性。我们使用基于定量逆转录聚合酶链反应的检测方法检查了 miRNA-205(mir-205)在组织中的表达情况,并证明其表达对鳞状上皮具有高度特异性。我们将该检测方法应用于组织样本,结果表明,每个阳性淋巴结标本中都可以检测到转移性 HNSCC,而良性标本则不表达该标志物。与来自其他原发性肿瘤的转移相比,HNSCC 阳性淋巴结可通过该标志物的高表达来区分。通过体外淋巴组织模型,我们能够在 100 万个淋巴细胞的背景下检测到低至一个鳞状细胞。通过将定量逆转录聚合酶链反应的灵敏度与 mir-205 对鳞状上皮的特异性相结合,我们证明了一种用于检测转移性 HNSCC 的新型分子标志物。